| 1. |
Harmon KA, Day AM, Hammill AM, et al. Quality of Life in Children With Sturge-Weber Syndrome. Pediatric Neurology, 2019, 101(1): 26-32.
|
| 2. |
Maiuri F, Gangemi M, Iaconetta G, et al. Sturge-Weber disease without facial nevus. Journal of Neurosurgical Sciences, 1989, 33(2): 215.
|
| 3. |
Huang L, Couto JA, Pinto A, et al. Somatic GNAQ mutation is enriched in brainendothelial cells in Sturge-Weber syndrome. Pediatric Neurology, 2017, 67(1): 59-63.
|
| 4. |
Ch'ng S, Tan ST. Facial port-wine stains-clinical stratification and risks ofneuro-ocular involvement. Journal of Plastic, Reconstructive & Aesthetic Surgery, 2008, 61(8): 889-893.
|
| 5. |
Dymerska M, Kirkorian AY, Offermann EA, et al. Size of facial port-wine birthmark may predict neurologic outcome in Sturge-Weber syndrome. The Journal of Pediatrics, 2017, 188(2): 205-209.
|
| 6. |
Pascual CI, Pascual PS, Velazquez FR, et al. Sturge-Weber syndrome. Study of 55 patients. Canadian Journal of Neurological Sciences, 2008, 35(3): 301-307.
|
| 7. |
Comi AM. Sturge-Weber syndrome and epilepsy: an argument for aggressive seizure management in these patients. Expert Review of Neurotherapeutics, 2007, 7(8): 951-956.
|
| 8. |
Sudarsanam A, Ardern-Holmes SL. Sturge-Weber syndrome: from the past to thepresent. European Journal of Paediatric Neurology, 2014, 18(3): 257-266.
|
| 9. |
Stafstrom CE, Staedtke V, Comi AM. Epilepsy Mechanisms in neurocutaneous disorders: tuberous sclerosis complex, Neurofibromatosis Type 1, and Sturge-Weber syndrome. Frontiers in Neurology, 2017, 8(1): 87.
|
| 10. |
王璐穎, 霍然. Sturge-Weber 綜合征特點及診斷治療研究進展. 中國美容整形外科雜志, 2016, 27(6): 329-333.
|
| 11. |
Torre DL, Alejandro J, Luat AF, et al. A multidisciplinary consensus for clinical care and research needs for Sturge-Weber syndrome. Pediatric Neurology, 2018, 84(1): 11-20.
|
| 12. |
Abdolrahimzadeh S, Scavella V, Felli L, et al. Ophthalmic alterations in the Sturge-Weber syndrome, Klippel-Trenaunay syndrome, and the phakomatosispigmentovascularis: An Independent Group of Conditions? Biomed Research International, 2015, 20(1): 1-11.
|
| 13. |
Kaplan EH, Kossoff EH, Bachur CD, et al. Anticonvulsant efficacy in Sturge-Weber syndrome. Pediatric Neurology, 2016, 58(1): 31-36.
|
| 14. |
Luat AF, Juhász C, Loeb JA, et al. Neurological complications of Sturge-Weber syndrome: current status and unmet needs. Pediatric Neurology, 2019, 98(1): 31-38.
|
| 15. |
Lance EI, Sreenivasan AK, Zabel TA, et al. Aspirin use in Sturge-Weber syndrome: side effects and clinical outcomes. Journal of Child Neurology, 2013, 28(2): 213-218.
|
| 16. |
Devinsky O, Pr of, Marsh E, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurology, 2016, 15(3): 270-278.
|
| 17. |
Kaplan EH, Offermann EA, Sievers JW, et al. Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome. Pediatric Neurology, 2017, 71(1): 18-23.
|
| 18. |
Ville D, Enjolras O, Chiron C, et al. Prophylactic antiepileptic treatment in Sturge-Weber disease. Seizure: European Journal of Epilepsy, 2002, 11(3): 145-150.
|
| 19. |
Day AM, Hammill AM, Juhász C, et al. Hypothesis: presymptomatic treatment of Sturge-Weber syndrome with aspirin and antiepileptic drugs may delay seizure onset. Pediatric Neurology, 2019, 90(1): 8-12.
|
| 20. |
Rezaei S, Abdurahman AA, Saghazadeh A, et al. Short-term and long-term efficacy of classical ketogenic diet and modified atkins diet in children and adolescents with epilepsy: a systematic review and meta-analysis. Nutritional Neuroscience, 2019, 22(5): 317-334.
|
| 21. |
Kossoff EH, Borsage JL, Comi AM. A pilot study of the modified atkins diet for Sturge-Weber syndrome. Epilepsy Research, 2010, 92(2): 240-243.
|
